NasdaqGS:IDYABiotechs
How IDEAYA’s Darovasertib NDA Push and Commercial Buildout At IDEAYA Biosciences (IDYA) Has Changed Its Investment Story
IDEAYA Biosciences recently outlined a busy 2026 for its oncology pipeline, highlighting positive Phase I/II data for darovasertib in first-line HLA-A2 negative metastatic uveal melanoma and plans for an FDA expedited review and NDA submission aimed at accelerated approval.
Alongside these clinical and regulatory steps, the company is already investing in commercial infrastructure, including sales leadership hires and supply-chain preparation, signaling a move toward potential...